The glutathione-S-transferase mu 1 ( GSTM1 ) null genotype and increased neutrophil response to low-level ozone (0.06 ppm)

PMN responsiveness was also confirmed to be independent of the spirometric (FEV1) response to low-level O3 in healthy subjects. Because GSTM1 is a risk factor for asthma exacerbation and O3, these data support the hypothesis that genetic modifiers of oxidative stress modulate the health effects of O...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2013-02, Vol.131 (2), p.610-612
Main Authors: Alexis, Neil E., PhD, Lay, John C., PhD, DVM, Zhou, Haibo, PhD, Kim, Chong S., PhD, Hernandez, Michelle L., MD, Kehrl, Howard, MD, Hazucha, Milan J., MD, PhD, Devlin, Robert B., PhD, Diaz-Sanchez, David, PhD, Peden, David B., MD
Format: Article
Language:English
Subjects:
Adult
Allergy and Immunology
Biological and medical sciences
Cytokines
Cytokines - genetics
Cytokines - immunology
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Genotype
Genotype & phenotype
Glutathione Transferase - deficiency
Glutathione Transferase - genetics
Glutathione Transferase - immunology
Humans
Immune system
Immunity, Innate - genetics
Immunity, Innate - immunology
Immunopathology
Inflammation - genetics
Inflammation - immunology
Medical sciences
Neutrophils - immunology
Ozone - immunology
Phagocytosis - genetics
Phagocytosis - immunology
Risk Factors
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PMN responsiveness was also confirmed to be independent of the spirometric (FEV1) response to low-level O3 in healthy subjects. Because GSTM1 is a risk factor for asthma exacerbation and O3, these data support the hypothesis that genetic modifiers of oxidative stress modulate the health effects of O3 in patients with allergic airways disease.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2012.07.005